Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.61 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.61 |
| ▸ | IL1RN | P18510 | 5/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30374944 | 0.96 | ERAP2 (0.61) | OPRK1KMT2AMEN1HCRTR1ERAP2 | |
| SCHEMBL20829962 | 0.96 | ERAP2 (0.61) | OPRK1KMT2AMEN1HCRTR1ERAP2 | |
| SCHEMBL20829913 | 0.93 | KMT2A (0.66) | KMT2AMEN1HCRTR1ERAP2IL1RN | |
| SCHEMBL30800609 | 0.93 | KMT2A (0.66) | KMT2AMEN1HCRTR1ERAP2IL1RN | |
| Hydrochloric Acid SCHEMBL11663648 | 0.92 | IL1RN (0.59) | OPRK1ERAP2IL1RNERAP1ANPEP | |
| SCHEMBL17534499 | 0.89 | MEN1 (0.61) | KMT2AMEN1HCRTR1ERAP2IL1RN | |
| SCHEMBL17534495 | 0.89 | MEN1 (0.61) | KMT2AMEN1HCRTR1ERAP2IL1RN | |
| SCHEMBL2182644 | 0.89 | LTA4H (0.69) | KMT2AMEN1ERAP2ERAP1ACE | |
| SCHEMBL2182648 | 0.89 | LTA4H (0.69) | KMT2AMEN1ERAP2ERAP1ACE | |
| SCHEMBL31477993 | 0.89 | LTA4H (0.69) | KMT2AMEN1ERAP2ERAP1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224609-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-01-18 | — | — | US | disclosed |
| US-20190083519-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNITED STATES GOVERNMENT | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224609-B2 | Mithramycin derivatives having increased selectivity and anti-cancer activity | TFAM, ELF3, TEAD4 | OPRK1 4074/4885KMT2A 93/4885MEN1 153/4885 |
| US-20190083519-A1 | MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | TFAM, ELF3, TEAD4 | OPRK1 4074/4885KMT2A 93/4885MEN1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.